Table 2.
Overview of biological treatment during pregnancy
| Author | Age, years | Therapy | Exposure, weeks of gestation | Delivery, week/mode | Breast cancer | Pregnancy complications | Birth weight, g | Neonatal status |
|---|---|---|---|---|---|---|---|---|
| Fanale 2005 [54] | 26 | vinorelbine 25mg/m2 weekly + trastuzumab weekly (1 cycle), further postpartum | 27–34.50 (1 cycle) | 34 + 5/vaginal | liver metastases | oligohydramnios; occasional fetal cardiac decelerations | 2,270 | male; no sequelae; status APGAR 9/9/- |
| Watson 2005 [59] | 28 | trastuzumab 580 mg 3 weekly over 5 months, then STOP | 0–23 (7 cycles) | 37 + 3/vaginal | primary | reversible anhydramnios at 23 weeks | 2,960 | female; no sequelae; status APGAR 8/9/- |
| Waterston and Graham 2006 [60] | 30 | trastuzumab 736 mg loading, 523 mg 2 cycles, then STOP | before conception, after 2.cycle T pregnant | week of delivery not reported/vaginal | primary | none | not reported | female; no sequelae; status APGAR not reported |
| Kelly 2006 [61] | 44 | lapatinib 750mg/day; stopped at 14 weeks | −0–11 | 36 | metastatic | none | 2,600 | female; no sequelae; status APGAR 8/9/- |
| Bader 2007 [62] | 38 | paclitaxel 175mg/m2, trastuzumab; stopped after 2 cycles | 25+6–26 (2 cycles) | 32 + 1/caesarean | metastatic spinal cord compression | oligo-anhydramnios; fetal growth retardation; fetal renal failure at 31 + 6 weeks | 1,460 | male; bacterial sepsis; hypotension; transient renal and respiratory failure |
| Sekar 2007 [63] | 28 | 3 docetaxel 190 mg + trastuzumab 2 cycles | 23–30 | 36 + 2 week/elective caesarean | lung metastases (20th week) | anhydramnios at 30th week; reversible fetal growth restriction (5th percentile) | 2,230 | male; no sequelae; status APGAR 7/9/5 |
| Shrim 2007 [64] | 32 | trastuzumab 400 mg, 3 weekly; stopped at 24 weeks | 0–24 | 37/elective caesarean | breast carcinoma, metastatic | reversible maternal heart failure, resolved slowly after discontinuation of trastuzumab | 2,600 | female; APGAR 9/10/NRD |
| Witzel 2007 [65] | 29 | 1st line: 24 cycles vinorelbine 25 mg/m2 + trastuzumab 2 mg/kg weekly, trastuzumab 6 mg/kg 3-weekly 25 cycles; total dose 56 mg/kg | 0–25, 23th week pregnancy diagnosis | 27/caesarean | invasive ductal, lung metastases, cerebral metastases under trastuzumab alone | oligohydramnios; vaginal bleeding | 1,015 | female; APGAR 8/7/6; pH = 7.48 umbil. artery; respiratory failure |